Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus
Investigators at University of Michigan zero in on hepatitis B virus
June 24th, 2008
"Purpose of review This is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2006 and November 2007. Recent findings Hepatitis A vaccine has similar efficacy to immune globulin as postexposure prophylaxis," scientists writing in the journal Current Opinion in Gastroenterology report. "Entecavir is a potent antiviral agent with a low rate of drug resistance in nucleoside-naive chronic hepatitis B patients but it is not as effective in lamivudine-refractory patients. A combination of adefovir and lamivudine is preferred to adefovir monotherapy for lamivudine-refractory hepatitis B patients. Two orally...
Source: Cancer Weekly (2008-06-24)
|
